MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance

MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-04, Vol.21 (9), p.3084
Main Authors: Desantis, Vanessa, Saltarella, Ilaria, Lamanuzzi, Aurelia, Melaccio, Assunta, Solimando, Antonio Giovanni, Mariggiò, Maria Addolorata, Racanelli, Vito, Paradiso, Angelo, Vacca, Angelo, Frassanito, Maria Antonia
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Apoptosis
Biosynthesis
Cancer
Cell growth
Clinical trials
Deregulation
Disease
Disease Progression
Disease resistance
Drug resistance
Drug Resistance, Neoplasm - genetics
Epigenetics
Exosomes
Gene expression
Gene Expression Regulation, Neoplastic
Gene Transfer Techniques
Humans
Kinases
lipid-based nanocarriers
Lipids - chemistry
Liposomes
Medical innovations
Medical prognosis
microRNAs
MicroRNAs - genetics
miRNA
Multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Multiple Myeloma - therapy
Nanotechnology
Nanotechnology - methods
Non-coding RNA
Nuclease
Pathogenesis
polymer-based nanocarriers
Polymers - chemistry
Post-transcription
Proteins
Review
RNA polymerase
RNAi Therapeutics - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation in the pathogenesis of multiple myeloma (MM), and discuss the potential use of miRs/nanocarriers association in clinic. Since miRs can act as oncogenes or tumor suppressors, strategies based on their inhibition and/or replacement represent the new opportunities in cancer therapy. The miRs delivery systems include liposomes, polymers, and exosomes that increase their physical stability and prevent nuclease degradation. Phase I/II clinical trials support the importance of miRs as an innovative therapeutic approach in nanomedicine to prevent cancer progression and drug resistance. Results in clinical practice are promising.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21093084